Dr. Alberts Discusses Updates in Liver Cancer

Steven R. Alberts, MD
Published: Monday, Sep 25, 2017



Steven R. Alberts, MD, professor of oncology in the College of Medicine, Mayo Clinic, discusses recent updates in liver cancer.

Until the approval of regorafenib (Stivarga) in 2017, the only FDA-approved agent for the treatment of hepatocellular carcinoma (HCC) was sorafenib (Nexavar).

At the 2017 ASCO Annual Meeting, data on lenvatinib (Lenvima) were presented, showing comparable results to sorafenib and is likely to be approved for patients with HCC, says Alberts.
 
SELECTED
LANGUAGE


Steven R. Alberts, MD, professor of oncology in the College of Medicine, Mayo Clinic, discusses recent updates in liver cancer.

Until the approval of regorafenib (Stivarga) in 2017, the only FDA-approved agent for the treatment of hepatocellular carcinoma (HCC) was sorafenib (Nexavar).

At the 2017 ASCO Annual Meeting, data on lenvatinib (Lenvima) were presented, showing comparable results to sorafenib and is likely to be approved for patients with HCC, says Alberts.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Navigating Treatment Decisions in mCRC: Sequencing Through Multiple Lines of CareMar 26, 20201.5
Community Practice Connections™: Optimizing Care in the Era of an Expanding Armamentarium for Hepatocellular CarcinomaMar 29, 20202.0
Publication Bottom Border
Border Publication
x